Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 5, 2000

View Archived Issues

Cephalon and Novartis join forces for U.K. marketing of CNS products

Inex reports significant Q3 developments

MorphoSys and ProChon Biotech reach milestone in HuCAL collaboration

Encouraging results reported from early clinical trial of VasoCare for PVD

INGN-241 is third Introgen drug candidate to enter clinical trials

deCODE Genetics establishes pharmacogenomics and cancer research subsidiaries

BioChem Pharma's Troxatyl to enter new clinical trial for CML-BP treatment

Affitech acquires exclusive rights to novel vaccine delivery technology

Phytopharm reports successful year-end results

Arrow Therapeutics and Virogen collaborate on RSV research

Genzyme Transgenics to produce huN901 for ImmunoGen

Effects of NK-104 on lipid profiles, atherosclerosis in WHHL rabbits

AxyS and Merck extend osteoporosis collaboration once again

Phase III trial examines efficacy of individualized dose adjustment for repinotan

Exogenous melatonin is protective in rat model of focal cerebral ischemia

Novel diagnostic agents targeting dopamine and 5-HT transporters

Thrombopoietin mimics emerge from SmithKline Beecham R&D

Anticancer tyrosine kinase inhibitors covered in patent issued to American Cyanamid

Bayer prepares new compounds active against HCMV

Androgen glycosides improve oral absorption of active ingredient

Chemically modified homoharringtonine analogue retains activity against resistant leukemia cells

Novel Bayer compound stimulates soluble guanylate cyclase

Recent patent covers GelTex's newest polymer bile acid sequestrants

Progress on Coagulin-B hemophilia B gene therapy reported at Hematology meeting

Hematology news: LY-294002 activates apoptotic pathway in myeloid leukemia cells

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...